Anti-MuSK myasthenia gravis with prolonged remission

التفاصيل البيبلوغرافية
العنوان: Anti-MuSK myasthenia gravis with prolonged remission
المؤلفون: Anne-Laure Bedat-Millet, Jean Paul Bouwyn, Patrick Ahtoy, David Maltête, Romain Lefaucheur, Patrick Magnier
المصدر: Neuromuscular Disorders. 26:453-454
بيانات النشر: Elsevier BV, 2016.
سنة النشر: 2016
مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Neuromuscular transmission, Gastroenterology, Asymptomatic, Diagnosis, Differential, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Adrenal Cortex Hormones, Internal medicine, Myasthenia Gravis, medicine, Humans, Receptors, Cholinergic, Repetitive nerve stimulation, Genetics (clinical), Autoantibodies, Diplopia, business.industry, Remission Induction, Receptor Protein-Tyrosine Kinases, Immunosuppression, medicine.disease, Dysphagia, Myasthenia gravis, Surgery, 030104 developmental biology, Neurology, Pediatrics, Perinatology and Child Health, Rituximab, Neurology (clinical), medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug
الوصف: Myasthenia gravis (MG) with antibodies against muscle-specific tyrosine kinase (MuSK) is a rare disorder of neuromuscular transmission affecting preferentially bulbar, neck and respiratory muscles. We report the case of a 22-year-old man who presented with diplopia on lateral gaze to both sides, facial diplegia, nasal dysarthria and dysphagia. Repetitive nerve stimulation of the trapezius and orbicularis oculi muscles showed amplitude decrements of 19% and 41% respectively supporting the diagnosis of myasthenia gravis. MUsK antibodies were positive. Corticosteroids were introduced and then tapered and discontinued at 6 months after initiation. The patient remained in remission and asymptomatic for 4 years without ongoing treatment or prior treatment with rituximab after this first relapse of MuSK-MG. MuSK- MG is considered a hard-to-treat condition and patients generally remain dependent on immunosuppression or prior treatment with rituximab. Our observation highlights that patients with MuSK-MG can have a benign course and that continued immunosuppressive or immunomodulatory therapy may not always be required.
تدمد: 0960-8966
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0126593d3a371cdce7355d604e6de68bTest
https://doi.org/10.1016/j.nmd.2016.04.008Test
حقوق: CLOSED
رقم الانضمام: edsair.doi.dedup.....0126593d3a371cdce7355d604e6de68b
قاعدة البيانات: OpenAIRE